This week we respond to some listener feedback from Dr. Christopher Booth and use it to talk about how to be the best hematologist-oncologist. We also discuss the SADAL study on Selinexor for patients with relapsed refractory diffuse large B-cell lymphoma, as published in The Lancet Haematology.
Finally, we interview Drs. Eva Katsoulakis and Michael Kelley on their recent paper out in the Journal of Clinical Oncology: Precision Oncology, titled "Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program".

Selinexor: doi.org/10.1016/S2352-3026(20)30120-4
Annotation Services: doi.org/10.1200/PO.19.00118

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: https://www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

2.60 BONUS! Cancer Meta-Research 101: The Lay of the Land of Cancer Research

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com